Abstract
One of the possibilities of anti-tumour treatment is the influence of tumour angiogenesis, triggering activation of thevascular endothelial growth factor (VEGFR) receptor, platelet growth factor (PDGFR) and fibroblast growth factor (FGFR).This treatment modality has also found its place in the treatment of advanced non-small cell lung cancer (NSCLC), whichis one of the most unfavourable tumours. First, bevacizumab was approved for treatment with NSCLC in combination withchemotherapy, later in the 2 nd line of treatment with nintedanib and ramucirumab in combination with chemotherapy.Recently, it has also been shown to be effective in combination with tyrosine kinase inhibitors receptor epidermal growthfactor (EGFR TKI) or immunotherapy.